Maximal aerobic power and blood pressure in normotensive subjects after acute and chronic administration of metoprolol
- PMID: 3987795
- DOI: 10.1007/BF00609682
Maximal aerobic power and blood pressure in normotensive subjects after acute and chronic administration of metoprolol
Abstract
The acute and long-term effects of the beta 1-adrenoceptor blocking agent metoprolol on blood pressure and maximal aerobic power (Wmax) were studied in 10 healthy subjects. Progressive maximal bicycle ergometer tests were performed after intravenous administration of placebo and metoprolol (0.15 mg . kg-1 and 0.30 mg . kg-1), and at the end of 4-week treatment periods with placebo, conventional metoprolol (C-M) and slow-release metoprolol (SR-M). The reduction in maximal exercise heart rate (HRmax) was correlated with the log plasma metoprolol concentration. Despite a reduction in HRmax of 23 beats/min after 0.15 mg . kg-1 metoprolol, Wmax was unaffected. After 0.30 mg . kg-1 HRmax was reduced by 40 beats/min and Wmax by 5.0%. During chronic treatment, the reductions in HRmax and Wmax were 48 beats/min and 7.5% (C-M) and 45 beats/min and 6.9% (SR-M), respectively. Resting systolic blood pressure was not changed after acute administration of metoprolol but it was reduced during chronic beta-blocker treatment. Resting diastolic blood pressure was not affected after acute or chronic treatment. Exercise systolic blood pressure remained unchanged after 0.15 mg . kg-1 metoprolol i.v. The fall in exercise systolic pressure after 0.30 mg . kg-1 metoprolol i.v. (18 +/- 5 mmHg) was significantly smaller than that during chronic treatment (30 +/- 6 mmHg C-M; 30 +/- 6 mmHg, SR-M). During chronic metoprolol treatment a certain % HRmax corresponded to a higher % Wmax than during placebo treatment, but the shift appeared to be of minor practical importance.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Effects of acute and chronic metoprolol administration during submaximal and maximal exercise.Int J Sports Med. 1985 Dec;6(6):347-52. doi: 10.1055/s-2008-1025869. Int J Sports Med. 1985. PMID: 4077364 Clinical Trial.
-
Maximal exercise power after a single dose of metoprolol and of slow-release metoprolol.Eur J Clin Pharmacol. 1980 Oct;18(3):225-9. doi: 10.1007/BF00563003. Eur J Clin Pharmacol. 1980. PMID: 7439241 Clinical Trial.
-
Pharmacological effects of concomitant administration of beta-adrenoceptor blocker and agonist in normal subjects: characterization by heart rate response to exercise. Effects of beta-blocker combined with beta-agonist.Eur J Clin Pharmacol. 1995;48(6):467-71. doi: 10.1007/BF00194336. Eur J Clin Pharmacol. 1995. PMID: 8582465 Clinical Trial.
-
Effect of controlled-release metoprolol on blood pressure and exercise heart rate in hypertension: a comparison with conventional tablets.Eur J Clin Pharmacol. 1988;33 Suppl:S33-7. doi: 10.1007/BF00578410. Eur J Clin Pharmacol. 1988. PMID: 3371392 Clinical Trial.
-
Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy.J Am Coll Cardiol. 1984 Jan;3(1):203-9. doi: 10.1016/s0735-1097(84)80449-0. J Am Coll Cardiol. 1984. PMID: 6140277 Clinical Trial.
Cited by
-
Exercise tolerance with nebivolol and atenolol.Cardiovasc Drugs Ther. 1992 Jun;6(3):239-47. doi: 10.1007/BF00051145. Cardiovasc Drugs Ther. 1992. PMID: 1353367 Clinical Trial.
-
[Have angiotensin-converting enzyme inhibitors improved therapy of hypertension?].Klin Wochenschr. 1988 Sep 15;66(18):920-3. doi: 10.1007/BF01728955. Klin Wochenschr. 1988. PMID: 3054277 Review. German.
-
The effect of verapamil on cardiovascular and metabolic responses to exercise.Eur J Appl Physiol Occup Physiol. 1986;55(5):499-502. doi: 10.1007/BF00421644. Eur J Appl Physiol Occup Physiol. 1986. PMID: 3095111 Clinical Trial.
-
Reduced ambulatory heart rate response to physical work and complaints of fatigue among hypertensive males treated with beta-blockers.J Behav Med. 1995 Apr;18(2):113-26. doi: 10.1007/BF01857864. J Behav Med. 1995. PMID: 7563041
-
Administration of slow-release nifedipine does not affect lactate threshold, hormone release during exercise, and quality of life in normal subjects.Cardiovasc Drugs Ther. 1992 Feb;6(1):85-90. doi: 10.1007/BF00050921. Cardiovasc Drugs Ther. 1992. PMID: 1576099 Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials